ARTICLE | Financial News
La Jolla in $125M royalty financing for Giapreza
May 10, 2018 11:43 PM UTC
La Jolla Pharmaceutical Co. (NASDAQ:LJPC) said it will receive $125 million from HealthCare Royalty Partners (Stamford, Conn.) in exchange for up to $225 million through tiered royalty payments on worldwide net sales of Giapreza angiotensin II.
FDA approved the renin-angiotensin system peptide agonist in December to increase blood pressure in adults with septic or other distributive shock. In its 1Q18 financial results reported Thursday the company said Giapreza posted $809,000 in 1Q sales. ...